The Biopharma Gap Eastern India Hasn't Noticed

Draw a line east of Hyderabad and look for a dedicated pharmaceutical or biotechnology manufacturing cluster. You will not find one. Not in West Bengal. Not in Jharkhand. Not in Chhattisgarh. Not in Odisha.

Eastern India — home to several hundred million people, with significant mineral and agricultural resources, and a coastline that connects to Southeast Asia — has no serious biopharma cluster. The entire eastern region is a gap in India's pharmaceutical industrial map.

That gap is also the opening.

Where India's pharma strength lives

India is the world's third-largest pharmaceutical producer by volume and among the largest exporters of generic medicines globally. The industry is genuinely world-class. But it is geographically concentrated in ways that are rarely examined.

Hyderabad's Genome Valley and the surrounding pharmaceutical industrial estate have made the city the dominant hub — hosting the bulk of India's vaccine manufacturing capacity and a significant share of its biotech research. Pune has a substantial cluster, with strong connections to the chemicals industry in western Maharashtra. Ahmedabad and the broader Gujarat corridor handle a large share of API (active pharmaceutical ingredient) manufacturing. Bengaluru has built research capability.

The pattern is clear: pharma clusters in western and southern India, research in the south, almost nothing in the east.

This is partly historical. Hyderabad's cluster began with deliberate state investment in the 1990s. Gujarat's chemical industry had infrastructure that made the transition to pharma manufacturing natural. Bengaluru's technology ecosystem extended into biotech. Eastern India lacked the equivalent catalysts.

But the conditions that produced those catalysts elsewhere are now available in Odisha in ways they were not two decades ago.

Why Odisha fits

First-mover arguments require more than an empty map. They require actual conditions that make the claimed position viable.

Odisha has a genuine case.

Port infrastructure is the starting point. Paradip is among the largest ports in India and handles significant industrial cargo. For a capital-intensive industry like biopharma — which depends on imports of raw material and intermediates and needs to export finished product — proximity to port infrastructure is a meaningful cost advantage. Hyderabad's pharmaceutical clusters are landlocked. Odisha's industrial zones can be port-adjacent.

The state has industrial land at scale. Odisha has been developing large-format industrial corridors along the coast — Dhamra, Gopalpur, Paradip — that have the land, power, and basic infrastructure that pharmaceutical manufacturing requires. The land acquisition challenges that hobble industrial development elsewhere in India are less acute here.

Water and power, both critical inputs for biotech manufacturing, are available. Odisha has historically had power surplus. The water-rich river systems of the state are an asset that pharma manufacturing consumes heavily.

The talent argument is the weakest part of the case, but it is not absent. Odisha produces significant numbers of science graduates — from KIIT, SOA, Utkal, Sambalpur — who currently migrate to work in pharma clusters elsewhere. A cluster in Odisha would not need to create the talent pool from scratch; it would need to retain what the state already produces.

What the moment is

India's Union Budget has in recent years signaled serious intent on building pharmaceutical and vaccine manufacturing capacity — specifically for export, and specifically to reduce dependence on Chinese API imports. That policy direction reduces investment risk for a new cluster. It means central government support for infrastructure, for PLI (production-linked incentive) schemes, for the regulatory environment that makes the investment viable.

The window created by that policy intent is not permanent. The states that move first to position themselves as the implementation sites for this ambition will capture the cluster formation. States that wait will find that the geography has been claimed.

The history of how industrial clusters form is consistent on this point: they form once, in a specific place, for path-dependent reasons, and they are extremely difficult to dislodge once formed. Hyderabad's pharma cluster exists because of decisions made in the 1990s. No one is rebuilding it in a different city.

Eastern India has a one-time opening to claim this. The biological reason it has not been claimed yet — no existing cluster to build around — is also the reason the claim is available.

The question of initiative

Industrial clusters do not form purely from geographic logic. They form because someone — a state government, a set of anchor investors, a combination of both — makes a deliberate choice to create the conditions and then does the work of attracting the first major investments that make the rest follow.

Odisha has done this before in steel, in aluminum, in power generation. The model is understood. The difference with biopharma is that the window is earlier and the first-mover advantage is larger — because the eastern India gap means there is genuinely no incumbent to compete against.

The case for Odisha as the biopharma capital of eastern India is not aspirational in the way that development targets sometimes are. It is geographically grounded, industrially coherent, and politically timely.

The question is not whether the opportunity exists. The question is whether it gets claimed before the moment passes.

That is a choice, not a forecast.